VYTRUS BIOTECH EO -01
Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. The company offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Ca… Read more
VYTRUS BIOTECH EO -01 (V5P) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, VYTRUS BIOTECH EO -01 (V5P) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
VYTRUS BIOTECH EO -01 - Net Assets Trend (None–None)
This chart illustrates how VYTRUS BIOTECH EO -01's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for VYTRUS BIOTECH EO -01 (None–None)
The table below shows the annual net assets of VYTRUS BIOTECH EO -01 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to VYTRUS BIOTECH EO -01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
VYTRUS BIOTECH EO -01 Competitors by Market Cap
The table below lists competitors of VYTRUS BIOTECH EO -01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Studsvik AB
ST:SVIK
|
$42.93 Million |
|
Appeninn Vagyonkezelo Holding Nyilvanosan Mukodo Reszvenytarsasag
F:0AP
|
$42.96 Million |
|
XBiotech Inc
NASDAQ:XBIT
|
$42.96 Million |
|
Enad Global 7 AB
ST:EG7
|
$42.96 Million |
|
Ledyard Financial Group Inc
OTCQX:LFGP
|
$42.92 Million |
|
Ya Horng Electronic Co Ltd
TW:6201
|
$42.91 Million |
|
Talenom Oyj
HE:TNOM
|
$42.88 Million |
|
Victoria plc
PINK:VCCTF
|
$42.85 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in VYTRUS BIOTECH EO -01's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares VYTRUS BIOTECH EO -01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently VYTRUS BIOTECH EO -01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares VYTRUS BIOTECH EO -01's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| VYTRUS BIOTECH EO -01 (V5P) | €- | N/A | N/A | $42.92 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |